You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News items for the week of Jan. 11, 2021.
Nuclei's technology, rooted in tissue imaging, will be used to search for biomarkers that predict patients' responses to one of Debiopharm's agents.
The agency approved the drug based on a study that showed an 88 percent response rate in young patients with ALK-positive anaplastic large cell lymphoma.
The precision oncology company plans to use the proceeds to advance drugs in its pipeline, improve its RADR platform, and acquire new therapeutic assets.
Drugmakers discussed advancing autologous CAR T-cell therapeutic programs, and several diagnostic firms detailed their efforts in precision oncology.
The Sentinel trial will enroll up to 100,000 patients with early-stage tumors to evaluate Strata's investigational liquid biopsy assay.
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
Using its xT sequencing platform, Tempus will create a companion test to identify patients eligible for treatment with A2's cell-based LOH-targeted therapy.
The company provides a cloud-based platform to help cancer centers with tumor board management, survivorship care planning, and clinical decision support.
The company is studying TAS0953/HM06 in roughly 200 patients in Japan and the US whose tumors harbor RET gene abnormalities.